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i 
Abstract 
Organophosphorus nerve agents are harmful chemical substances that inhibit 
acetylcholinesterase activity. This impedes hydrolysis of the neurotransmitter 
acetylcholine at synapses in the brain and at neuromuscular junctions. Because of this, 
muscles in the body do not get the appropriate signal for muscle contraction. This leads to 
a number of side effects, including eventual death by asphyxiation. These chemical 
weapons have been used throughout modern history, including the use of Sarin in the 
1995 subway terrorist attack in Tokyo by the Aum Shinrikyo religious group and more 
recently in Syria by rebel terrorist groups. These agents have been designed based on 
insecticides, specifically organophosphorus agents, because of their extreme toxicity 
toward higher vertebrae organisms. Civilians in many third world countries are fatally 
poisoned due to the toxicity of these insecticides. To provide protection against these 
insecticides and even organophosphorus nerve agents, Paraoxonase-1 (PON1) has been 
observed to have some catalytic efficiency for the agents. This esterase is found in serum 
at concentrations close to 50 µg/L, and has low activity to hydrolyze the more toxic 
isomer of these OP agents. Through directed evolution and protein engineering, a mutant 
of PON1 could be designed to have a high enough catalytic efficiency to hydrolyze the 
toxic isomer of these agents and eventually be administered to humans for protection.  
 Paraoxonase-1 is a 42 kDa calcium dependent esterase. It exhibits a six-bladed 
propeller tertiary structure with two calcium sites. In serum, PON1 is synthesized in the 
liver and circulates within HDL (high density lipoproteins) particles. Because it binds to 
HDL, it is suggested that PON1 may play an important role in atherosclerosis prevention 
and reverse cholesterol transport. PON1 primarily acts as a lactonase in vivo, but has 
ii 
some activity for organophosphorus agents. Because of this, it is a novel candidate as a 
catalytic bioscavenger. Using directed evolution via gene shuffling of rabbit, human, 
mouse, and rat PON1 genes, the Weizmann Institute expressed chimeric recombinant 
PON1 enzyme (G3C9) in high yield in bacteria to use as a model for studying PON1 
activity. This wildtype, G3C9, has a modest amount of activity towards these OPs and 
nerve agents. The organophosphorus agents such as GB, GD, VX, and VR all have 
stereoisomers and are synthesized as racemic mixture. Interestingly, the SP-isomer of all 
these compounds is more toxic. G3C9 has little to no activity for the SP-isomer of these 
molecules. However, through a number of rounds of directed evolution a mutant called I-
1-F11 has been found to have a higher affinity for the SP-isomer rather than the less toxic 
RP-isomer, hydrolyzing the SP-CMP-Coumarin analogue of CMP at a rate of 12.1 µM
-1
m
-
1
. Because of this, I-1-F11 can be used as a model to improve the stereoselectivity of 
PON-1, which could eventually lead to an enzyme with close to diffusion limited activity 
towards the more toxic isomer of OP agents and insecticides. I-1-F11 differs by seven 
different residues from the wildtype, G3C9. These mutations include L55M, L69V, 
H115A, H134R, F222M, I291L, and T332S. By using site-directed mutagenesis of PON-
1, the importance of these residues for stereoselectivity can be determined and other 
mutations significant for stereoselectivity can be identified. From our studies, all seven 
mutations appear to play a significant role in the stereoselectivity of 1-I-F11, especially 
L55M and L69V which have the most effect.  
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Chapter 1 
Introduction 
1.1 OP compounds and nerve agent poisoning prevalence 
 Organophosphorus (OP) compounds have become some of the most prominently 
used pesticides over the past century due to their extreme level of toxicity. These 
compounds have been synthesized to increase stability and specificity for esterase 
inhibition in vivo, thereby obstructing many important biological functions and 
pathways.
1
 Acute organophosphorus compound poisoning developed into a global health 
issue in the 1990’s, with approximately 25 million episodes of intoxication occurring 
annually among agricultural workers alone.
2
 Today, approximately 3 million of these 
incidents involve severe cases of poisoning, resulting in 220,000 deaths each year.
3
 These 
incidents usually involve relatively high amounts of exposure when compared with nerve 
agents, which are OP compounds originally synthesized to inhibit acetylcholinesterase. 
The first synthesized OP compound, tabun, was developed by the German chemist 
Gerhard Schrader in 1936 as a chemical warfare agent with an LD50 of 4000 
mg/individual.
4
 Throughout WWII, other nerve agents such as soman and sarin were 
developed with even lower LD50’s and thus posed more dangerous threats to the world’s 
populations.
4
 Reemergence of nerve agents, especially sarin, has been observed despite 
the U.N.’s banning of chemical warfare agent production at the Chemical Weapons 
Convention in 1993. On August 21, 2013, the U.N. investigated an incident near 
Damascus, Syria, in which hundreds of men, women, and children were killed.
5
 For 
numerous research labs, identification of sarin gas and its degradation products presented 
a challenge previously tackled in Saddam Hussein’s use of chemical weapons in Iraq 
2 
during the 1980s and the Tokyo subway attack involving sarin in 1995.
5
 The current 
global prevalence of chemical weapon utilization as well as pesticide poisoning thus 
suggests a need for the development of a counteraction providing protection against these 
compounds. Our enzyme of interest, paraoxonase-1 or PON1, is one of the primary 
targets for providing protection from poisoning by mode of acetylcholinesterase 
inhibition.  
 
1.2 Acetylcholinesterase biological function and action 
 As stated previously, the primary mode of OP compound poisoning occurs via 
acetylcholinesterase inhibition. Acetylcholinesterase (AChE) is integral in biological 
movement and function, especially due to its role in the central and peripheral nervous 
systems. AChE is an extrinsic, membrane-bound enzyme that is responsible for the 
hydrolysis of the neurotransmitter acetylcholine (ACh).
6
 In regularly functioning 
neurons, an action potential reaches the presynaptic nerve process causing ACh to diffuse 
across the synapse and bind to proximate ACh receptors. This leads to a cascade which 
opens K
+
 and Na
+
 channels in the adjacent axon or axons, eventually triggering an action 
potential in the postsynaptic neuron. To terminate this process, AChE hydrolyzes ACh 
into choline and acetate. Acetylcholinesterase possesses high specific activity that is 
diffusion limited, exhibiting a steady-state rate constant in the conversion of free enzyme 
and free substrate of 10
8
 M
-1
s
-1
.
6
 This aspect of acetylcholinesterase makes it an 
evolutionary “perfect” enzyme and is a product of its molecular structure.  
 
1.3 Acetylcholinesterase structure-function relationship 
3 
The crystal structure of a homodimer of AChE (from the species Torpedo 
californica)  form was solved using a hanging-drop vapor diffusion method and the 
presence of a catalytic triad consisting of residues S200, E327, and H440 has been 
confirmed (in mice, the residues have consist of S203, E334, and H447 respectively).
78
 
Also along these lines, recent Born—Oppenheimer ab initio QM/MM molecular 
dynamics simulations with umbrella samplings have been able to characterize AChE 
hydrolysis of ACh.
9
 These studies show that the reaction is initiated by nucleophilic 
attack by the catalytic histidine, resulting in a high-energy tetrahedral covalent 
intermediate that is stabilized by an oxyanion hole formed by peptidic NH groups from 
G118, G119, and A201.
8
 This reaction mechanism is impeded through inhibition by OP 
compounds. Nerve agents exhibit their toxicity by phosphonylating the catalytic serine of 
the serine side chain.
10
 Typically, anticholinesterase OP compounds are either phosphoric 
or phosphonic acid derivatives and can be sulfur analogs. These compounds also usually 
consist of two alkyl substituents and a third substituent which acts as the leaving group.
11
 
After covalently bonding to the substrate, AChE is essentially irreversibly inhibited and 
shows slow to non-existent reactivation due to a process called aging. In this aging 
process, the dealkylation of the diakylphosphonyl enzyme results in a more stable 
monoalkylphosphonyl enzyme which has negligible rates of reactivation.
11
 This 
mechanism has recently been supported through QM/MM studies with soman, showing 
an overall exothermic reaction in the formation of the stable “aged-AChE.”10  
Figure 1.1: Active site of aged phosphylated  
TcAChE determined by X-ray crystallography
12
 
4 
 
1.4 AChE Inhibition Effects 
Inhibition of AChE can have a number of physiological repercussions. Toxicity 
varies amount compounds, but typically only very low doses are needed to induce 
seizures and other related biological responses. When initially intoxicated, victims follow 
a three-phased process of poisoning. In general, these episodes are initiated by an early 
cholinergic phase which lasts from the onset of seizure and approximately five minutes 
afterward. This step is followed by a phase of mixed cholinergic/non-cholinergic 
modulation which continues for approximately 40 minutes, which is subsequently 
accompanied by a non-cholinergic phase.
13
 In the case of human poisoning, symptoms 
include miosis, seating, rhinorrhea, lacrimation, salvation, abdominal cramps and other 
GI issues, respiratory difficulties, dyspnea, bradycardia, anorexia, nausea, vomiting, 
5 
diarrhea, involuntary urination and defecation, as well as damage to functions of the 
central nervous system which is associated with dizziness, confusion, and headaches. 
These symptoms are then typically followed by seizures, convulsions, mood swings, and 
other psychiatric issues. Death usually occurs due to respiratory failure in instances of OP 
poisoning.
14
  
  
1.5 Stoichiometric sequestration of organophosphorus compounds 
 A number of methods have been developed to combat organophosphorus 
poisoning. Some of these methods are preventative, while others attempt to reactivate 
acetylcholinesterase after inactivation due to covalent binding of OP compounds to the 
catalytic site serine. Therapeutics designed for protection and/or biological function 
restoration are developed usually through one of three different methods: catalytic 
hydrolases, stoichiometric binding agents, or pseudo-catalytic treatments that use 
catalytic activity only in the presence of oximes.
15
 Cholinesterases, and in particular 
butyrylcholinesterase (BChE), have been studied extensively as potential bioscavengers. 
HuBChE has proven to be capable of providing protection against a number of nerve 
agents such as tabun, sarin, soman, and VX via stoichiometric sequestration.
16–18
 
Recombinant human acetylcholinesterase has also been found to have similar to possibly 
higher levels of prophylactic protection, however only binding to the SP-enantiomer of 
OPs.
19
 Thus rHuAChE does not bind the RP-enantiomer of these compounds, making 
BChE more efficient at sequestering a racemic mixture of OPs. In addition, rHuAChE is 
relatively unstable in human serum, but subsequent PEGylation displays a mean 
circulatory retention time of approximately 10,000 min.
1820
 In addition to these 
6 
challenges, commercial and large scale production of AChE is still limited.
21
 To stand a 
reasonable chance at providing protection in vivo, substantial stability becomes a 
necessity. Although the reported values vary, BChE demonstrates a half-life ranging 
somewhere between 44.7 h to approximately 10 days.
22
 Whatever the case, BChE has 
sufficient stability to make it a viable drug when administered preventatively, although 
protection by these methods are solely through stoichiometric sequestration .
15
  
 
1.6 Pseudo-catalytic and catalytic bioscavengers 
 Progress has also been made in the production and design of pseudo catalytic 
bioscavengers which have the capability to be regenerated, usually through oxime-
mediated reactions. Because BChE has proven as the currently most viable option for 
stoichiometric sequestration of OPs, it is a primary area of research for pseudo catalytic 
treatments. Attempts at mutating BChE and AChE have been attempted to elicit catalytic 
hydrolysis from these previously stoichiometric bioscavengers, however most these 
efforts have failed or resulted in minimal actvivity.
21
 Reactivation of paraoxon-inhibited 
AChE and BChE, as well as tabun-inhibited BChE, has been achieved through treatment 
with a number of different oximes.
23,24
 A more attractive approach at this moment in time 
appears to be treatment with purely catalytic bioscavengers, possibly administered as a 
mixture containing supplementary stoichiometric bioscavengers if necessary. Some of 
these catalytic bioscavengers include but are not limited to phosphotriesterase (PTE), 
organophosphorus hydrolase (OPH), diisopropyl fluorophosphatase (DFP), Drp35, 
senescence marker protein 30 (SMP-30), and paraoxonase 1 (PON1).
25–28
 Most of the 
research, however, has been conducted on SMP-30, DFPase, and PON1. From this point 
7 
onward, the focus of the text will be fixated upon PON1 pertaining to discovery, 
biological significance, and most importantly its potential as a bioscavenger. 
 
1.7 PON1 discovery and physiological function 
 The discovery of PON1 is accredited to Dr. Abraham Mazur in 1946 when he was 
analyzing inhibition of plasma, red blood cells, and brain cholinesterases by diisopropyl 
flurophosphate within a number of tissue samples.
29
 He came across the observation that 
rabbit plasma and human tissue samples have catalytic hydrolysis activity towards 
organophosphorus compounds, although very minimal activity. Today, PON1 today is 
known as a member of the paraoxonase gene family, consisting of members PON1, 
PON2, and PON3.
30
 PON1 is a 43-45 kDa glycoprotein that is synthesized in the liver 
and then secreted into the serum where it circulates bound to high-density lipoprotein 
(HDL).
30,31
 There is evidence that PON1 is implicated in atherosclerosis, possibly by 
protecting against low-density lipoprotein (LDL) oxidative stress by reducing 
macrophage foam cell formation and therefore reduction of atherosclerosis 
development.
32
 A number of PON1 gene polymorphisms have been associated with a 
various human diseases, including coronary heart disease, Parkinson’s disease, type 2 
diabetes, and inflammatory bowel disease.
33–35
 It is believed that the primary biological 
function of PON1 is its capacity to hydrolyze lipid peroxides, preventing foam cell 
formation and hence atherosclerosis,
32
 however work is still being done on the subject. 
Because it is already present within the human body in serum, PON1 presents a viable 
option as a bioscavenger with a potentially negligible immunogenic response, thus 
making it advantageous in drug delivery. In the attempts of designing PON1 as a 
8 
potential bioscavenger, one must consider humanization or in vivo stability, catalytic 
efficiency, and substrate specificity.  
 
1.8 PON1 structure  
 There is a significant amount of literature on mutagenesis of PON1 aiming to 
increase catalytic efficiency, however the exact mechanism of its reactivity is still 
unclear. In 2004, the first crystal structure of PON1 was solved giving some insight into a 
possible mode of reactivity. Through directed evolution using gene shuffling from 
human, rabbit, mouse, and rat PON1 sequences, the variant G2E6 was crystalized.
31
  
Figure 1.2: Serum Paraoxonase by Directed Evolution
31
 
 
This mutant, having 91% homology with WT rabbit PON1, has mutations that 
presumably do not interfere with the active site of the protein. From the crystal structure, 
9 
it was determined that PON1 is a six-bladded β-propeller containing one disulfide bridge 
and two calcium ions within the core.
31
 The tertiary structure PON1 resembles that of a 
number of other enzymes, including diisopropylfluorophosphatase and SMP-30.
36,37
 It is 
also believed that the hydrophobic N-terminal signal peptide is necessary for association 
with HDL in vivo and is also responsible for binding to the lipoprotein molecule.
38
 The 
binding mode of PON1 to HDL is not entirely understood, however Apolipoprotein A-I 
stabilizes PON1 in vitro and could quite possibly be implicated in PON1 and HDL 
interactions. 
38
 Although the structure of PON1 has been solved, the mechanism of 
PON1’s enzymatic activity is still unknown and will be the focal point of this discussion.  
 
1.9 PON1 substrate promiscuity 
Investigation of the mechanism of PON1 has led some to believe that PON1 was 
selected by nature as a lactonase in a recent paper looking at the evolution of the three 
mammalian PON families.
39
 Its possible physiological substrate could be homocysteine 
thiolactone as it is in the only known molecule with homothcystrine thiolactonase activity 
found within the body. PON1 also exhibits excellent hydrolysis activity towards phenyl 
acetate with a kcat/KM of 10
6
 M
-1
 s
-1
.
40
 Most importantly, PON1 has some 
phosphotriesterase activity, although mostly likely did not evolve as a phosphotriesterase 
because these substrates are synthetic and have only been in existence on Earth for the 
past several decades.
40
 HuPON1exhibits differences in activity toward a number of 
substrates (such as V-type nerve agents, phenyl acetate, and paraoxon) in comparison 
with G2E6 and rabbit PON1 (G3C9).
41
 These discrepancies suggest that even though the 
variation in residues did not occur within the active site itself, effects on activity were 
10 
still observable and that the global orientation of the protein was altered.
41
 Figure 1.9 
demonstrates the 3 primary modes of activity of PON1 with reactions a, b, and c which 
correlate to lactonase, esterase, and phosphotriesterase activity respectively.
42
 
Figure 1.3: Catalytic versatility of Paraoxonase 1
42
 
 
1.10 PON1 catalytic mechanism 
The promiscuity of PON1’s enzymatic activity alludes to the mystery of its 
catalytic mechanism. It is generally accepted that the active site of the protein is located 
at the upper calcium.
31
 The exact active site reside, however, has not been identified. 
Originally, it was believed that His134 within the active site acts as a proton acceptor to 
increase the basicity of His115, forming a His-His dyad in which His115 activates a 
11 
water molecule through deprotonation which then serves as the nucleophile within the 
reaction.
31
 However, recent variants of PON1 simultaneously lacking histidine at both 
115 and 134 still exhibit lactonase/arylesterase activity and thus it has been proposed that 
there are multiple residues within the active site that are capable of producing hydrolytic 
activity.
43
 Some have tried to investigate enzymes with similar structure and function, 
including SMP-30 and DFPase, to demystify the mode of activity. By superimposing the 
three enzymes upon each other, similarities in the binding pocket and metal ion 
geometry, flexible loop position and implication, and β-sheet blade locations are all 
observable.
37
 DFPase, PON1, and SMP-30share a flexible loop near the active site. In 
PON1, it is theorized that movement of this loop is involved with substrate binding by 
moving in and out of the active site.
37
 As for the geometry of the active site, the residues 
responsible for metal ion binding are relatively well conserved. In PON1, the ligands 
include E53, N168, N224, N270, and D269. Figure 1.4 illustrates the metal-binding 
residues of all three enzymes, showing the similarities between all three.  
Figure 1.4: Comparison of active sites of DFPase, Hu PON1, and Hu SMP-30
37
  
 
The most significant difference between PON1 and the other two enzymes are the 
subpockets of the active site, consisting of subpockets 1 and 2. The first subpocket in 
PON1 is composed of residues L69, F347, and H115, while the second subpocket 
includes residues F222, L240, L267, and F292. The secondary hydrophobic pocket 
12 
allows for substrate specificity due to its high hydrophobicity, thus providing stability for 
a myriad of substrates with large hydrophobic groups in comparison to DFPase and SMP-
30. More recent studies of PON1 suggest an alternative hypothesis for the mechanism of 
PON1 activity. A more recent crystal structure of rePON1 has been solved at a new pH of 
6.5, rather than the previous 4.5 pH of the past structure, giving further insight into the 
enzymatic activity of PON1.
42
 In the crystal structure, PON1 inhibitor 2HQ (2-
hydroxyquinoline) is bound to the active site calcium. 
Figure 1.5: 2HQ within the active site
42
 
 
In figure 1.5, one can see that the flexible loop containing residues 71-81 lies above the 
13 
active site. This loop can be anchored to the surface of the enzyme where Y71 points into 
the active site. In this state, PON1 is considered to be in the closed conformation. In the 
open conformation, the active site flexible loop is unanchored from the surface of protein 
and moves freely.
42
 Because this crystal structure was obtained in the closed 
conformation with 2HQ bound in the active site, it is believed that during substrate 
binding the flexible loop “closes” overtop of the active site of PON1. Docking studies 
using a variety of substrates were then performed assuming this closed conformation. 
Figure 1.6: Molecular docking of PON1 variant G2E6 with various substrates
42
 
 
Figure 1.5 illustrates substrate binding with the S-isomer of γ-nonanoic lactone (a), 
14 
phenylacetate (b), paraoxon (c), and dihydrocoumarin (d). While docking γ-nonanoic 
lactone, phentylacetate, and dihydrocoumarin with PON1 in closed conformation were 
successful, attempts at docking paraoxon within the active site in the closed conformation 
were not. Y71 is the principal residue involved in inhibiting the binding of PON1 in this 
confirmation, however when mutated to a smaller residue such as alanine, paraoxon 
hydrolysis activity is significantly decreased. It is thus believed that binding of paraoxon 
within the active site occurs in the open confirmation.
42
 Also, when docking these 
substrates within the active site, there appears to be differences between the primary 
residues interacting with the substrates. Phenylacetate and γ-nonanoic lactone display 
close interactions with H115, while paraoxon and dihydrocoumarin show interactions 
with residues E53 and D268. Currently, the most accepted mechanism of PON1 activity 
depends upon the substrate. The theorized lactonase activity is depicted in figure 1.7.  
Figure 1.7: Hydrolysis of lactones by rePON1 
 
Under this model, a hydroxide nucleophile is generated via general base catalysis by E53 
15 
and H115 in regards to lactonase activity. With respect to paraoxon and 
dihydrocoumarin, an alternative mechanism must be considered due to absence of effects 
on activity when mutating out H115. Proposed mechanisms include nucleophilic attack 
by the side chains of E53, D269, or other residues within the active site. Another possible 
mode of catalysis could be water activation by E53 or D269.
42
 Along with the issues in 
understanding the mechanism of PON1, another challenge arises when analyzing the 
mechanistic properties. Namely, the stereochemistry involved in these reactions becomes 
relevant if PON1 is to be used as a bioscavenger. 
 
1.11 PON1 stereoselectivity 
As stated previously, AChE binds preferentially to the SP isomer of OPs.
19
 Past 
attempts at improving the catalytic efficiency of PON1 has been unsuccessful in selecting 
for activity towards the Sp isomer of these compounds until recently.
44–46
 Directed 
evolution using high-throughput fluorescence-activated cell sorting (FACS) and low-
throughput plate screening has been utilized to improve catalytic efficiency relatively 
rapidly while screening against various nerve agents.
46
 By screening against the 
stereoisomers of these compounds, mutations can be selected to improve preferential 
reactivity for the SP isomer. Through this process, a number of variants have been 
designed with improved reactivity for the SP isomer of G-type agents.
45,46
 G-type nerve 
agents such as tabun (GA), sarin (GB), soman (GD) and cyclosarin (GF) are some of the 
most highly toxic organophosphates, penetrating the body by either inhalation or skin 
absorption. These OPs have LD50’s ranging from approximately 0.071-0.714 mg/kg;
45,47
 
according to theorized models, prophylactic activity on the order of ~10
7
 M
-1
 min
-1
 would 
16 
be necessary for protection against OPs of such extreme toxicity. In particular, the PON1 
variant 1-I-F11 was found after 3 rounds of screening starting from the variant 2D8. 2D8 
contains the mutations L69G, S111T, H115W, H134R, F222S, and T332S from WT 
PON1, G3C9.
46
 Mutant 1-I-F11 contains the mutations L55M, L69V, H115A, H134R, 
F222M, I291L, and T332S and has an activity of 12.1 • 106 M-1 min-1 towards the Sp 
isomer of CMP-coumarin, the coumarin analog of GF.
45
 Figure 1.8 depicts SP and RP 
isomers of both GF and CMP.  
Figure 1.8: G-type nerve agent stereochemistry 
 
WT PON1 has negligible catalytic activity for this substrate, either the Sp or RP isomer, 
whereas 1-I-F11 has an extremely high activity for the SP isomer and essentially no 
activity for the RP isomer with a 2575 fold difference in kcat/KM.
45
 The exact reason 
behind this inversion in reactivity for the SP isomer is not entirely understood, although it 
has been theorized that the combination of mutations I291L and T332S play a crucial role 
in this specificity. From this point, we attempted to understand the stereoselectivity of the 
variant 1-I-F11 through various methods. 
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Chapter 2 
Objectives 
2.1 Design and study of PON1 chimeric mutants 
 1-I-F11 differs from WT PON1 (G3C9) by seven residues near the active site of 
the enzyme. No crystal structure of 1-I-F11 currently exists, so mutagenesis and analysis 
of variants with enzyme kinetics will be implemented to understand the stereoselectivity 
of the variant for the Sp isomer of OPs. This presents a challenge of selecting what 
mutations to make, such as single mutations, pairs, or even groups of mutations. One 
could potentially design thousands of variants with any one of these sets of mutations, so 
a rational approach must be taken in deciding what route of mutagenesis to implement. 
The first step of this project was to analyze a group of mutations from 1-I-F11 to 
determine if only a certain few residues are responsible for stereoselectivity before 
making individual mutations to 1-I-F11.  
 
2.2 Design and study of 1-I-F11 single point mutants 
 It is possible that a single residue can have significant implications on the 
stereoselectivity of the enzyme. Singe point mutants of 1-I-F11 could be engineered by 
reverting the seven mutated residues back to the G3C9 amino acid at that position. Single 
mutations of PON1 would allow for easier analysis of changes in catalytic activity and 
possibly more insight into the mechanism of PON1 activity, especially the 
stereoselectivity for the Sp isomer of CMP found in the PON1 variant 1-I-F11.  
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Chapter 3 
Materials and Methods 
3.1 Design and study of PON1 chimeric mutants 
Gene construction of chimeric mutants 
G3C9 and 1-I-F11 constructs were obtained from our collaborator Dan S. Tawfik 
at the Wiezmann Institute. To investigate a group of mutations, our rationale was to 
divide the mutations according to DNA sequence for ease and uncertainty in what group 
of mutations to select. A location between residues 134 and 222 thus seemed appropriate, 
as one could design two chimeric mutants by splitting the mutations up at this location. 
Below is a plasmid map of the G3C9 plasmid along with selected restriction sites. 
Figure 3.1: G3C9 plasmid map 
 
 
In the digestion reaction was 50 µL of G3C9 or 1-I-F11 miniprep, 3 µL of both enzymes, 
10 µL of NEBuffer #4 (New England BioLabs, Inc.), and 5 µL of 18MΩ-cm water. The 
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reaction was allowed to persist for 2 hours and was subsequently loaded onto a 1% 
agarose DNA gel. The insert and vector bands were cut from the gel and then gel purified 
following QIAquick Gel Extraction Kit Protocol. After gel purification, the insert from 
the G3C9 plasmid was ligated into the remaining 1-I-F11 vector; likewise, the 1-I-F11 
insert was ligated into the remaining G3C9 vector. These ligations were performed using 
1:5 and 1:10 ratios of insert to vector based on size of the DNA fragments and 1 µL of T4 
DNA ligase with T4 DNA ligase buffer (New England BioLabs, Inc.).The ligation 
reactions were carried out at 16 ºC overnight and then transformed into DH10B E. coli 
cells via electroporation. Cells were plated onto LB agarose plates with ampicillin, grown 
overnight at 37 ºC, and then stored at 4 ºC. Individual colonies were picked and 
minipreps following QIAprep Spin MiniPrep Protocol were performed. Samples were 
then sent to GENEWIZ, Inc. for sequencing to confirm that the correct sequence had 
been produced. These two new variants were named 1-I-F11-G3C9 and G3C9-1-I-F11, in 
which each contained the following amino residues at the relevant positions with the WT 
residues listed in red. 
Table 3.1: Chimeric variants with corresponding mutations 
Variant Residues 
1-I-F11-G3C9 M55, V69, A115, R134, F222, I291, T332 
G3C9-1-I-F11 L55, L69, H115, H134, M222, L291, S332 
 
3.2 Design and study of 1-I-F11 single point mutants 
Gene construction of single point mutants 
Selected amino acids were replaced by site-directed mutagenesis of the 1-I-F11 
gene using QuikChange Site-Directed Mutagenesis protocol. Below is a list of the 
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primers designed for all of the single point mutations of 1-I-F11: 
Table 3.2: Site-directed mutagenesis primers for single point mutants 
Variant Forward Primer Reverse Primer 
1-I-F11-M55L 
GAC AAT GGT TCT GAA 
GAC TTA GAA ATA CTG 
CCC AAT GGA CTG 
CAG TCC ATT GGG CAG 
TAT TTC TAA GTC TTC 
AGA ACC ATT GTC 
1-I-F11-V69L 
GCT TTC ATC AGC TCC 
GGA CTC AAG TAT CCT 
GGA ATA ATG 
CAT TAT TCC AGG ATA 
CTT GAG TCC GGA GCT 
GAT GAA AGC 
1-I-F11-A115H 
GAT ATA TCT TCA TTT 
AAC CCT CAC GGG ATT 
AGC ACA TTC 
GAA TGT GCT AAT CCC 
GTG AGG GTT AAA TGA 
AGA TAT ATC 
1-I-F11-R134H 
CTA CTG GTG GTA AAC 
CAC CCA GAC TCC TCG 
TCC ACC 
GGT GGA CGA GGA 
GTC TGG GTG GTT TAC 
CAC CAG TAG 
1-I-F11-M222F 
GCA GAA GGA TTT GAT 
TTC GCT AAC GGA ATC 
AAC 
GTT GAT TCC GTT AGC 
GAA ATC AAA TCC TTC 
TGC 
1-I-F11-L291I 
CCC AAC GGA ATG 
CGA ATC TTC TAC TAT 
GAC CCA AAG 
CTT TGG GTC ATA GTA 
GAA GAT TCG CAT TCC 
GTT GGG 
1-I-F11-S332T 
GTA TTA CAG GGC AGC 
ACA GTG GCC GCT GTG 
TAC 
GTA CAC AGC GGC CAC 
TGT GCT GCC CTG TAA 
TAC 
 
Each PCR reaction was digested with DpnI overnight before transformation into DH10B 
cells. All the samples were sent for sequencing to confirm successful mutagenesis.  
 
1-I-F11-HA tag cloning 
 To improve the sensitivity of samples for in vivo testing, a hemagglutinin (HA) 
tag was introduced on the C terminus of the 1-I-F11 gene with the following primers: 
Forward primer: GGTGGTGGTCCATG GCTAAACTGACAGCGCTCAC 
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Reverse primer: GGG GCC GCA CTT GAG CAC CAC CAC CAC CAC CAC TAC 
CCA TAC GAC GTC CCA GAC TAC GCT TGA GAT CCG CTC GAG AAA CCC. 
After successful ligation, the samples were sent for sequencing.  
 
Blank mutant gene construction 
 After calculating activities of all variants toward racemic CMP and SP-CMP, we 
decided to construct another mutant of 1-I-F11 containing the mutations M55L, V69L, 
and A115H. Double digestions of both G3C9 and 1-I-F11 were performed with the 
restriction enzymes NcoI and BseRI. The insert from the G3C9 digestion was then ligated 
into the remaining 1-I-F11 vector and the samples were sent for sequencing to ensure 
proper ligation.   
 
Protein expression and purification 
All PON1 variants were overexpressed in BL21 (DE3) from colonies or glycerol 
stocks in 1 L 2YT media containing 1 mM CaCl2. Cells were grown at 37 ºC until log 
phase, which occurred at approximately 0.8 OD at 600 nm, and were then induced to 0.1 
mM IPTG while lowering the temperature to 30 ºC for 4 h. Cell pellets were harvested 
after spinning the cell cultures at 5000 rpm for 10 min at 4 ºC and stored at -80 ºC. For 
purification, all steps were carried out at 4 ºC . were then  resuspended in lysis buffer (50 
mM Tris pH 8, 50 mM NaCl, 1 mM CaCl2, 1 mM BME ) in approximately 10 volumes of 
total solution to 1 volume of cell pellet. After cells were lysed via sonification, 0.1% 
tergitol was added to the cell lysis and incubated for 2.5 h while shaking at 4 ºC. Cell 
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lysis was then centrifuged at 12,000 RPM for 30 min at 4 ºC and the supernatant was 
transferred to a clean 50 mL falcon tube. Approximately 2-3 mL of Ni-NTA slurry 
(Qiagen) was washed with activity buffer (50 mM Tris pH 8, 50 mM NaCl, 1 mM CaCl2, 
1 mM BME, 0.1% tergitol) plus 10 mM imidazole and then added to the supernatant to 
incubate while shaking on a Nutator for 3 h at 4 ºC. The resin was then loaded on a 
washed 25 mL column and the unbound material was allowed to flow through the 
column. The resin was then washed with 50 mL of wash buffer 1 (activity buffer 
containing 10 mM imidazole) and 15 mL of wash buffer 2 (activity buffer containing 25 
mM imidazole). The desired PON1 bound to the Ni-NTA resin due to the 6×His-tag was 
then eluted with 30 mL of elution buffer (activity buffer containing 150 mM imidazole). 
Samples collected from protein purification were analyzed with SDS-PAGE (12.5% 
agarose). Fractions containing PON1 were dialyzed into activity buffer with 10% 
glycerol 2 h followed by dialysis into activity buffer with 50% glycerol for 3 h. 
Concentrations of PON1 were then determined with Bradford protein assay, which was 
confirmed visually using SDS-PAGE.  
 
Western blot 
 Purified protein with variable concentrations mixed with SDS loading buffer were 
heated at 95 ºC for 10 min. Samples were loaded and run on a 12.5% SDS-PAGE gel and 
transferred to a nitrocellulose membrane (GE healthcare). After blocking with BSA for 1 
h at room temperature, the blots were incubated overnight at 4 ºC with anti HA-tag 
antibody (1:5000 dil) (Millipore). The membrane was subsequently incubated with a 
secondary antibody, goat anti mouse IgG (1:200 dil) conjugated to horseradish 
23 
peroxidase and developed using a chemiluminescent detection system followed by 
scanning using a Typhoon (GE lifescience). 1-I-F11 WT without HA tag was used as a 
control. 
 
Enzyme kinetics with racemic CMP 
 CMP was synthesized by the Hadad group as a racemate and dissolved into 
methanol. To assess concentration of dissolved substrate, CMP was hydrolyzed with the 
PON1 variant 3B3 which turns over only the RP isomer of CMP, thus hydrolyzing half of 
the total amount of CMP in solution
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. The purified variants were then tested for their 
activity against racemic CMP. First, 186 µL of assay buffer (50 mM Tris pH 8, 10 mM 
CaCl2) and 4 µL racemic CMP were added to a well of a 96-well microassay plate, after 
which 10 µL of appropriated diluted enzyme was added to the well and immediately 
placed into an M5 spectrophotometer and then plotted absorbance versus time. The slope 
was measured within the linear portion of each trial where it was assumed the substrate-
enzyme complex remained constant. All kinetic parameters were collected by Michaelis-
Menten steady-state kinetics. A Michaelis-Menten plot can be made by plotting the slope 
obtained from the change in absorbance over time (mM min
-1
) versus concentration of 
the substrate in each reaction.   
Figure 3.2: Michaelis-Menten equation 
   
       
      
 
Above is the Michaelis-Menten equation where Vmax is kcat[E]t. Experimentally, KM is the 
concentration of substrate at half Vmax. Vmax is the horizontal asymptote of the curve. If 
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the concentration of substrate is much smaller than KM, it is possible to extract the 
enzymatic efficiency (kcat/KM) by simply dividing the rate by the substrate and enzyme 
concentration. However, if the substrate concentration is much larger than the KM value, 
it is possible to obtain the catalytic activity (kcat) of the enzyme by dividing the rate by 
the enzyme concentration. The kcat/KM is the most common value use in reporting 
enzymatic activity. Each variant was tested against four different concentrations of 
racemic CMP and the kcat/KM was determined by plotting absorbance per min versus 
concentration of racemic CMP by using the known extinction coefficient (ԑ) equal to 
37450 M
-1
 cm
-1
 for CMP. 
 
Enzyme kinetics with SP-CMP 
 To prepare SP-CMP, racemic CMP was hydrolyzed with the PON1 variant 3B3 
overnight to ensure complete hydrolysis of RP-CMP.  This reaction contained 181 µL  
assay buffer, 4 µL  CMP, and 5 µL  diluted 3B3. After overnight incubation, PON1 
variants were reacted with the remaining SP-CMP by adding 10 µL of PON1 to 190 µL of 
the reaction mixture. Activity towards SP-CMP was calculated using single point kinetics.  
 
Molecular docking with SP-CMP 
 Molecular docking was performed by Kate Cahill from the Hadad research group 
using AutoDock. Images of SP-CMP bound to the calcium within the active site were 
obtained to help visualize the effects of the 1-I-F11 mutations. 
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Chapter 4 
Discussion and Results 
4.1 Design and study of PON1 chimeric mutants 
I-F11-G3C9 and G3C9-I-F11 gene construction 
To swap the N-terminal portions of 1-I-F11 and G3C9, the digested inserts (Fig. 
4.1) were ligated into the appropriate vector and the samples were confirmed by 
sequencing.  
Figure 4.1: Double restriction digest of 1-I-F11 and G3C9 
 
The sequences were aligned (Fig. 4.2) to confirm the correct sequence of all new 
variants.  
Figure 4.2: Sequence alignment using ClustalW2 
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Expression and purification 
All variants were expressed similarly to the WT. No changes were observed in the 
yield of product. The following gel is a good indication of the yield achieved from the 
purification of each variant. 
Figure 4.3: G3C9 purification 
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1-I-F11-HA tag and western blot 
 To overcome detection limitations of the CMP assay with in vivo studies, an HA 
tag was introduced on the C terminus of 1-I-F11 and the sequence was confirmed. The 1-
I-F11 HA tag variant expressed well (Fig 4.4).  
Figure 4.4: 1-I-F11-HA tag purification 
 
After successful purification, we wanted to determine the lowest possible limit of protein 
detection by Western blot. From the following gel, the lowest possible protein amount we 
can detect from Western blot using HA tag antibody is approximately 2 ng (Fig 4.5).  
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Figure 4.5: 1-I-F11-HA tag Western blot                    
 
1-I-F11-HA tag kinetics 
We wanted to see whether the HA tag had any effect on the activity of 1-I-F11. 
After performing kinetics on 1-I-F11-HA tag, a kcat/KM of 7000 mM
-1
 min
-1
 against 
racemic CMP was calculated. Compared to the kcat/KM of 15000 mM
-1
 min
-1
 against 
racemic CMP of 1-I-F11 WT, about a 2 fold decrease was observed. This was small 
enough of a change in activity to allow for in vivo studies to be conducted with 1-I-F11-
HA tag.  
 
Chimeric mutant kinetics 
Table 4.1: CMP activity summary of chimeric variants 
Mutant 
SP-CMP  
(mM
-1
min
-1
) 
Racemic CMP 
(mM
-1
min
-1
) 
RP-CMP 
(mM
-1
min
-1
) 
RP/SP 
1-I-F11 4200 15000 10800 2.6 
I-F11-G3C9 50 2300 2250 50 
G3C9 3.8 1020 1016 270 
G3C9-I-F11 3.6 150 146.4 40.7 
 
   PON1 (ng):   150      75      37.5   18.5     9.5      5        2.5       1.2       0.5     0.2    0.1    0.05     0.025   
0.01   
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 Table 4.1 illustrates the activities of G3C9, 1-I-F11, and the two chimeric 
mutations. Below (Fig. 4.4) is a depiction of a typical Michaelis-Menten plot. 
Figure 4.6: Michaelis-Menten plot 
 
RP-CMP was calculated by simply subtracting the activity against SP-CMP from the 
activity against racemic CMP. From the results, one can see a drastic loss in 
stereoselectivity for SP-CMP in both chimeras. The N-terminal mutations of M55L, 
V69L, A115H, and R134H in G3C9-I-F11 appear to have both a significant impact on 
the activity against both racemic CMP and SP-CMP. However, G3C9-IF11 still maintains 
a similar ratio of RP-CMP to SP-CMP activity in comparison to I-F11-G3C9. Thus, both 
sets of mutations are important for the stereoselectivity of PON1. Specifically, the 
residues in M55, V69, A115, and R134 appear to be more influential in the activity of 
PON1 towards CMP when compared to M222, L291, and S332.  
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4.2 Design and study of 1-I-F11 single point mutants 
Cloning, expression, and purification 
 Because the chimeric variants did not provide enough clues into the 
stereoselectivity of PON1, we decided to make single mutants of 1-I-F11 to understand 
the effects of each individual amino acid. All single point mutants were cloned using site-
directed mutagenesis and sent for sequencing. All sequences were confirmed and then 
expressed and purified. As with the chimeric mutants, no significant changes were seen 
in protein production and yield.  
Kinetics 
Table 4.2: CMP activity summary of 1-I-F11 single point variants 
Mutant 
SP-CMP 
(mM
-1
min
-1
) 
Racemic CMP 
(mM
-1
min
-1
) 
RP-CMP 
(mM
-1
min
-1
) 
RP/SP 
1-I-F11 4200 15000 11000 2.7 
1-I-F11-L291I 530 3200 2700 5.1 
1-I-F11-R134H 760 5600 4800 6.3 
1-I-F11-M222F 760 5200 4590 6.1 
1-I-F11 BLANK 27.2 300 272.8 10.0 
1-I-F11-S332T 208 2300 2100 10.1 
1-I-F11-A115H 45.8 650 650 14.2 
1-I-F11-M55L 355 7000 6900 19.4 
1-I-F11-V69L 140 3400 3260 23 
G3C9 3.8 1020 1020 270 
 
Table 4.2 illustrates the activities of G3C9, 1-I-F11, and single point mutants of 1-
I-F11. Overall, all 7 mutations appear to have a significant effect on the racemic CMP 
activity of PON1. However, not much of a difference in the ratio of RP-CMP to SP-CMP 
activity was seen in some of the mutants. In particular, mutations M55L and V69L had 
the most drastic decrease in this ratio, and thus are most likely the mutations with the 
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largest impact on the stereoselectivity of 1-I-F11.  
Molecular docking of CMP 
Figure 4.7: Molecular docking of SP-CMP in G3C9 active site 
 
Figure 4.8: Molecular docking of SP-CMP in 1-I-F11 active site 
 
 Based upon these images, molecular docking studies suggest that R134, L291, 
and S332 are the mutations most accountable for the reversion of stereoselectivity of 1-I-
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F11. They allow for a more stable binding of CMP to the active site calcium in an anti- 
conformation with the theorized active site nucleophile, D269. These results, however, go 
against the results found in the kinetics summary above.  
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Summary and Future Directions 
 In this project, we attempted to understand the stereoselectivity of 1-I-F11with the 
end goal of improving PON1’s efficacy as a bioscavenger. The data obtained from the 
chimeric variants indicated that both the N-terminal and C-terminal mutations were 
important for the stereoselectivity of the enzyme with the 4 n-terminal mutations having 
more of an impact on the overall activity towards CMP and SP-CMP. With somewhat 
inconclusive results, we decided to make a series of single mutants reverting the 
mutations in 1-I-F11 back to the amino acid found in G3C9. These results showed that of 
the seven mutations, L55M and L69V were most important in the stereoselectivity of 1-I-
F11. At this point, we are attempting to construct a series of single mutants of G3C9, 
performing the opposite process of the 1-I-F11 single mutants. Here, we will be 
converting the G3C9 residues into those found in 1-I-F11 and looking for which 
mutations produce the high stereoselectivity for SP-CMP. In addition, we would like to 
construct a library randomizing position 71 to see how mutations at this position can 
affect the activity of PON1. Y71 is known to be influential in substrate binding due to its 
positing over the opening into the active site. Also, at the moment thermal stabilities are 
being conducted to understand the stability effects of the mutations in 1-I-F11. 
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